Compare · BSX vs LUNG
BSX vs LUNG
Side-by-side comparison of Boston Scientific Corporation (BSX) and Pulmonx Corporation (LUNG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and LUNG operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 1106.7x LUNG ($59.1M).
- BSX has been more active in the news (2 items in the past 4 weeks vs 1 for LUNG).
- BSX has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Boston Scientific Corporation
- Pulmonx Corporation
- Price
- -
- -
- Market cap
- $65.44B
- $59.1M
- 1M return
- -
- +11.65%
- 1Y return
- -
- -56.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 1
- Recent ratings
- 25
- 17
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Latest LUNG
- Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
- Director Burns Thomas William was granted 40,000 shares, increasing direct ownership by 54% to 113,399 units (SEC Form 4)
- Director Ferrari Richard was granted 40,000 shares, increasing direct ownership by 46% to 127,024 units (SEC Form 4)
- Director Florin Daniel P was granted 40,000 shares, increasing direct ownership by 43% to 133,910 units (SEC Form 4)
- Director Melenikiotou Georgia was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
- Director Sullivan Tiffany was granted 40,000 shares, increasing direct ownership by 53% to 115,199 units (SEC Form 4)
- Director Mead Dana G Jr. was granted 40,000 shares, increasing direct ownership by 40% to 139,714 units (SEC Form 4)
- Pulmonx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Science &Techn. Officer Radhakrishnan Srikanth sold $22,325 worth of shares (14,497 units at $1.54), decreasing direct ownership by 4% to 331,239 units (SEC Form 4) to cover withholding tax
- GENERAL COUNSEL Lehman David Aaron sold $22,475 worth of shares (14,594 units at $1.54), decreasing direct ownership by 4% to 376,161 units (SEC Form 4) (withholding obligation)